Evolving Takeda Signals Intent To Build Around Entyvio, GI Franchise
Executive Summary
Deals with TiGenix and Altos add to a growing gastrointestinal pipeline, as the Japanese pharma sees Entyvio and GI, not Velcade and cancer, as its primary growth-driver.
You may also be interested in...
Is Takeda's Consumer Unit 'Agile' Enough To Stretch Outside Japan?
Takeda says spinning off its consumer product portfolio into a wholly owned and independent subsidiary will boost its profile in the sector, but all signs continue to point to the firm's Rx operations as its predominant revenue drivers.
Is Takeda's Consumer Unit 'Agile' Enough To Stretch Outside Japan?
Takeda says spinning off its consumer product portfolio into a wholly owned and independent subsidiary will boost its profile in the sector, but all signs continue to point to the firm's Rx operations as its predominant revenue drivers.
Takeda Funds Celiac Asset As Prelude To Potential Acquisition
Takeda has started off the new year by continuing down the path of partnerships to strengthen its core therapeutic areas, this time linking up with a US academic spin-out for a potential oral therapy for celiac disease.